Healthcare / Pharmaceutical RetailersHKSE
$0.42
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $54.9M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$249M
P/E
21.0x
↑EV/EBITDA
4.3x
↓ROE
1.8%
↑Gross Margin
27.0%
↓Debt/Equity
0.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.4%
FCF CAGR
-16.1%
FCF margin
6.0%
FCF / Net income
4.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $917.3M · net income $11.3M · FCF $54.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $917.3M | $917.3M | $1.06B | $1.08B | $957.7M |
| Net Income | $11.3M | $11.3M | $41.6M | $38.1M | $22.7M |
| EBITDA | $97.5M | $97.5M | $129.0M | $125.5M | $118.1M |
| EPS | 0.02 | 0.02 | 0.07 | 0.06 | 0.04 |
| Gross Margin | 27.0% | 27.0% | 25.5% | 26.0% | 29.0% |
| Operating Margin | 5.5% | 5.5% | 6.5% | 5.8% | 6.6% |
| Net Margin | 1.2% | 1.2% | 3.9% | 3.5% | 2.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.70 | 0.70 | 0.63 | 0.57 | 0.47 |
| Current Ratio | 1.09 | 1.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $54.9M | $54.9M | $94.7M | $-63.3M | $93.0M |
| Returns | |||||
| ROE | 1.8% | 1.8% | 6.5% | 6.2% | 3.7% |
| Valuation | |||||
| P/E | 21.00 | 21.00 | 6.30 | 9.78 | 27.47 |
| EV/EBITDA | 4.26 | 4.26 | 3.33 | 4.41 | 5.70 |
| P/B | 0.40 | 0.40 | 0.41 | 0.60 | 1.02 |
| Growth & Yield | |||||
| Revenue Growth | -13.5% | -13.5% | -1.6% | 12.6% | — |
| EPS Growth | -73.4% | -73.4% | 12.1% | 71.7% | — |
| Dividend Yield | 7.6% | 7.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
24.7%
EPS terminal req.
$0.04
Spread vs growth
-98.1%
5Y implied EPS CAGR
18.6%
EPS terminal req.
$0.05
Spread vs growth
-92.0%
10Y implied EPS CAGR
14.2%
EPS terminal req.
$0.07
Spread vs growth
-87.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.3%
Start / end P/E
8.2x → 21.9x
EPS bridge
0.07 → 0.02
Residual
-123.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.